The COVID-19 pandemic is affecting us all to some extent. However, many pathogens more easily infect those who have concurrent illnesses or are immunocompromised, such as patients with cancer. Prognosis is likely worse in these patients. As the number of COVID-19 cases in China began to plateau in mid-February, doctors started to evaluate outcomes among […]

PD-1 inhibitors have become a mainstay of treatment for many cancers in recent years. However, while these agents are associated with a robust response in some patients, the majority of patients will progress. Several trials have evaluated potential combination strategies to bolster responses to PD-1 inhibitors, but there is no clear consensus in this area. […]

According to an analysis of the PREVAIL and AFFIRM clinical trials, development of new bone lesions in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) who are stable or responding to enzalutamide is a form of pseudoprogression that does not necessarily impact long-term outcomes. The study evaluated outcomes in 1672 patients treated with enzalutamide on […]

Each year the American Society of Clinical Oncology (ASCO) releases a report highlighting the greatest clinical advances in cancer research and treatment for the past year. In the most recent report, released in early February, ASCO president Howard “Skip” Burris III, MD, named the refinement of surgical treatment of cancer as the Advance of the […]

The major news in recent months has been the emergence and spread of a novel coronavirus, COVID-19 (formerly known as 2019nCoV). To help clinicians sort fact from fiction regarding this new virus and infection, a primer was recently published in JAMA. This provides background on the origin and spread of COVID-19, common signs and symptoms […]

While children and older adults with acute lymphoblastic leukemia (ALL) are treated at pediatric and adult cancer centers respectively, adolescents and young adults (AYAs; 15 to 39 years) represent a unique patient group that can be treated in either setting. According to a recent report evaluating patterns of care, only 32.3% of AYA patients are […]

Racial disparities in cancer treatment and outcomes are common and well-documented. According to a new study published in JAMA Oncology, minority patients with cancer also experience disparities in the cultural competency of their physician, including access to physicians who understand their culture. The study evaluated patient data from 2244 adult cancer survivors participating in the […]

Immunotherapies have become a standard treatment for many patients with cancer. While these agents can be highly effective and associated with durable responses and improved long-term survival, they are also associated with a unique and potentially serious adverse event profile. Appropriate management of immune-related adverse events (irAEs) is essential for successful treatment with immunotherapies. To […]

While hundreds of clinical trials in lung cancer are completed each year, results from many trials will not be publicly released or published in a peer-reviewed journal. According to a study published in JAMA Network Open, results from as many as 25% of lung cancer clinical trials are never published. Researchers evaluated phase II and […]

While cyclin-dependent kinase (CDK)4/6 inhibitors have become a mainstay of treatment for patients with hormone receptor-positive (HR+), HER2-negative (HER2–) metastatic breast cancer (mBC), many patients still receive first-line treatment with chemotherapy, even in the absence of visceral crisis. Lacking head-to-head clinical trials comparing treatment approaches, a recent meta-analysis compared results from phase II and III […]